Detalles de la búsqueda
1.
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Clin Infect Dis
; 76(4): 674-682, 2023 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35906831
2.
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study.
Am J Hematol
; 95(7): 749-758, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32233095
3.
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
Ann Hematol
; 94(12): 1981-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26410352
4.
Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.
Haematologica
; 102(2): e47-e51, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27789677
5.
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.
Cancers (Basel)
; 12(11)2020 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33187229
6.
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
J Clin Oncol
; 34(9): 972-9, 2016 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26811524
7.
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
J Clin Oncol
; 32(3): 219-28, 2014 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-24297940
Resultados
1 -
7
de 7
1
Próxima >
>>